



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Koenig et al

Serial No: 09/645,835

Art Unit: 1653

Filed: 25 August 2000

Examiner: Kam, C.

TITLE: PNEUMOCOCCAL PROTEIN HOMOLOGS AND FRAGMENTS FOR VACCINES

Docket No.: 469201-493

RECEIVED

24 March 2003

Commissioner for Patents
Washington, D.C. 20231

APR 03 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

___ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

X §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

04/01/2003 EAREGAY1 00000102 09645835

01 FC:1806

180.00 OP

is accompanied by either: (check one)

☐ The statement as specified in 37 CFR §1.97(e) set out below;
OR

☒ The fee of \$180.00 under 37 CFR §1.17(p).

☐ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

☐ §1.97(e) The undersigned Attorney hereby states that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 09/645,835
Filed: 25 August 2000



FIRST CLASS CERTIFICATE

I hereby certify that this
correspondence is being deposited today
with the U.S. Postal Service as First Class
Mail in an envelope addressed to: Box
Patent Applicaion

Commissioner for Patents
Washington, D.C. 20231

Alan J. Grant

Alan Grant, Esq.

Date 3/24/03

Respectfully submitted,

Alan J. Grant

Alan Grant, Esq.

Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Tel: (973)994-1700

Fax: (973)994-1744

#84133 v1 - ids form

RECEIVED

APR 03 2003

TECH CENTER 1600/2900